Paul Blake, a veteran pharmaceutical executive, has been named chief development officer at Oxford BioMedica Plc, the UK developer of gene and cell therapies. He is currently a non-executive director and will remain on the board after he assumes his new position on 1 September. Dr Blake has been a member of the board since January 2010. He has more than 30 years of experience in the industry including most recently as chief medical officer at Aeterna Zentaris Inc, a specialty biopharmaceutical company.
Dr Blake qualified in medicine at the Royal Free Hospital School of Medicine, London University and is a fellow of the Royal College of Physicians and a fellow of the American College of Clinical Pharmacology.
Oxford BioMedica announced the appointment on 15 August 2014.
Copyright 2014 Evernow Publishing Ltd